Adverse Outcome Pathways (AOPs) are becoming increasingly important in regulatory toxicology for facilitating use of mechanistic data, test paradigm development, predictive toxicology, and risk assessment. It is critical that experts with knowledge in specific areas of biology become involved in both developing and reviewing AOPs, to ensure that regulatory practices are based on the most recent knowledge, data, and test systems. Genotoxicity-associated AOPs are currently in development. Now is the time for the EMGS to become involved in this important effort.
Find out the basics and discuss how the EMGS (and you) might become involved through participating in this webex. Wed, Jan 22, 2020 12:00 PM - 1:30 PM EST